Commissioning of 6 MV UNIQUE Performance Medical Accelerator: Dosimetric Evaluation and TPS Validation using AAPM TG -119 and IAEA CIRS Test Cases

To test the overall accuracy and quality of IMRT and VMAT plans following AAPM TG119 and IAEA test recommendation and to validate the test plans for clinical implementation by comparing the calculated and measured doses. The recommendations in AAPM TG119 include planning objectives, dose delivery and measurement conditions for different clinically relevant and common test cases of IMRT& VMAT. IAEA end-to-end audit performed on CIRS phantom to test the overall accuracy of all treatment modalities. The phantom was made to undergo similar processes to a patients undergoing radiotherapy. For cases planned with TG119 recommendation the gamma analysis and point dose measurements were performed. The mean dose observed for IMRT in point dose measurement found to be -0.08 % and Confidence Limit obtained were: a) point dose measurements 0.56 % b) measured gamma analysis is 4.66 c) Portal dosimetry (PD) gamma analyses is 0.12. VMAT plans shows mean dose variation for point dose measurement is 0.30 % and Confidence Limit obtained were: a) point dose measurements 1.15 b) measured gamma analysis is 3.46 (1 ARC)& 3.35 (2 ARC) c) gamma analysis is 0.85 (1 ARC)& 1.36 (2 ARC). IAEA test shows maximum point dose variation 2.149 % in VMAT.